News
Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...
Pfizer (NYSE:PFE) develops and sells biopharmaceutical products, including vaccines, treatments for infectious diseases, ...
Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback